07:05 AM EST, 11/24/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said that its weight-loss drug semaglutide failed to meet its primary endpoint of reducing Alzheimer's progression in two phase 3 trials enrolling a total of 3,808 adults.

The drug failed to show a statistically significant reduction in disease progression compared with a placebo combined with standard of care, the company said.

Treatment with semaglutide showed improvement in some related biomarkers but did not slow the advancement of the disease, the company said.

Shares of the company were down 9.5% in recent premarket activity.